Aslani S, Alluri P, Gudmundsson E, Chandy E, McCabe J, Devaraj A, Horst C, Janes SM, Chakkara R, Alexander DC, Nair A, and Jacob J
Lung cancer screening (LCS) using annual computed tomography (CT) scanning significantly reduces mortality by detecting cancerous lung nodules at an earlier stage. Deep learning algorithms can improve nodule malignancy risk stratification. However, they have typically been used to analyse single time point CT data when detecting malignant nodules on either baseline or incident CT LCS rounds. Deep learning algorithms have the greatest value in two aspects. These approaches have great potential in assessing nodule change across time-series CT scans where subtle changes may be challenging to identify using the human eye alone. Moreover, they could be targeted to detect nodules developing on incident screening rounds, where cancers are generally smaller and more challenging to detect confidently. Here, we show the performance of our Deep learning-based Computer-Aided Diagnosis model integrating Nodule and Lung imaging data with clinical Metadata Longitudinally (DeepCAD-NLM-L) for malignancy prediction. DeepCAD-NLM-L showed improved performance (AUC = 88%) against models utilizing single time-point data alone. DeepCAD-NLM-L also demonstrated comparable and complementary performance to radiologists when interpreting the most challenging nodules typically found in LCS programs. It also demonstrated similar performance to radiologists when assessed on out-of-distribution imaging dataset. The results emphasize the advantages of using time-series and multimodal analyses when interpreting malignancy risk in LCS., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Shahab Aslani reports financial support was provided by Cancer Research UK. Joseph Jacob reports financial support was provided by Wellcome Trust Clinical Research Career Development Fellowship. This work was supported by Cancer Research UK (C68622/A29390). The authors thank the National Cancer Institute for access to NCI’s data collected by National Lung Screening Trial (NLST). The statement contained herein are solely those of the authors and do not represent or imply concurrence or endorsement by NCI. J.J and this research was supported by Wellcome Trust Clinical Research Career Development Fellowship 209553/Z/17/Z. For the purpose of open access, the author has applied a CC-BY public copyright licence to any author accepted manuscript version arising from this submission. This project, J.J, E.G, SH.A, SM.J, A.N and DC.A were also supported by the NIHR UCLH Biomedical Research Centre, UK. The SUMMIT Study is funded by GRAIL LLC. through a research grant awarded to SM.J as Principal Investigator. SM.J is supported by CRUK programme grant (EDDCPGM/100002), and MRC Programme grant (MR/W025051/1). SM.J receives support from the CRUK Lung Cancer Centre of Excellence (C11496/ A30025) and the CRUK City of London Centre, the Rosetrees Trust, the Roy Castle Lung Cancer foundation, the Longfonds BREATH Consortia, MRC UKRMP2 Consortia, the Garfield Weston Trust and University College London Hospitals Charitable Foundation. SM.J’s work is supported by a Stand Up To Cancer-LUNGevity- American Lung Association Lung Cancer Interception Dream Team Translational Research Grant and Johnson and Johnson (grant number: SU2C-AACR-DT23-17 to S.M. Dubinett and A.E. Spira). Stand Up To Cancer is a division of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the Scientific Partner of SU2C.This work was partly undertaken at UCLH/UCL who received a proportion of funding from the Department of Health’s NIHR Biomedical Research Centre’s funding scheme. J.J reports consultancy fees from Boehringer Ingelheim, F. Hoffmann-La Roche, GlaxoSmithKline and NHSX. J.J reports advisory boards in Boehringer Ingelheim and F. Hoffmann-La Roche. J.J reports lecture fees from Boehringer Ingelheim, F. Hoffmann-La Roche, and Takeda. J.J reports grant Funding from GlaxoSmithKline, Wellcome Trust, Microsoft Research and Gilead Sciences. J.J reports patents UK patent application numbers 2113765.8 and GB2211487.0. J.J was supported by Wellcome Trust Clinical Research Career Development Fellowship 209553/Z/17/Z. SM.J has received fees for advisory board membership in the last three years from Bard1 Lifescience. SM.J has received grant income from GRAIL Inc. SM.J is an unpaid member of a GRAIL advisory board. SM.J has received lecture fees for academic meetings from Cheisi and Astra Zeneca. SM.J’s wife works for Astra Zeneca. SM.J reports fees from Astra-Zeneca, Bard1 Bioscience, Achilles Therapeutics, and Jansen unrelated to the submitted work. SM.J received assistance for travel to meetings from Astra Zeneca to American Thoracic Conference 2018 and from Takeda to World Conference Lung Cancer 2019 and is the Investigator Lead on grants from GRAIL Inc, GlaxoSmithKline plc and Owlstone. A.N reports advisory fees from Part-funded by UCLH Biomedical Research Centre (BRC), National Institute for Health Research (NIHR); Member of Advisory Board, Aidence, Artificial Intelligence BV; Co-Investigator, Integration and Analysis of Data Using Artificial Intelligence to Improve Patent Outcomes with Thoracic Diseases (DART) study; Scientific Advisory Board, iDx Lung Trial; Collaborator/Advisory fees Merck Sharp and Dohme (MSD) (UK) Limited; Speaker Fees, Astra Zeneca (AZ) UK Ltd. A.D’s disclosures are fees from Boehringer Ingelheim, Roche, Brainomix, and Vicore. P.A and R.C are the founder of ManasAI, an AI SaaS company specializing in predictive models. P.A and R.C. own equity in ManasAI. SH.A, E.G and DC.A is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. E.CH, J.M and C.H have no competing interests to declare. The remainder of the SUMMIT consortium declare no competing interest with regard to the current manuscript., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)